摘要
目的探讨不同免疫抑制方案对移植肾术后早期功能的影响及安全性比较。方法将3种不同的免疫抑制方案分别用于肾移植患者。A组:CsA+Aza+Pred,、B组:CsA+MMF+Pred、C组:FK506+MMF+Pred。根移植肾早期功能状态,统计A、B、C3组患者1年移植肾存活率,急性排斥发生率及移植肾功能恢复情况,药物副作用等。结果在3组患者中比较,B组和C组移植肾1年存活率高于A组;C组的急性排斥发生率均低于A组、B组(P<0.05)。同时,C组的肝功能损害,肾毒性发生率明显低于A组、B组(P<0.05)。结论通过临床不同免疫抑制方案的比较,认为应用MMF和FK506组成的免疫抑制方案,具有更高的安全性,可减少急性排斥反应,药物毒副作用的发生率,提高肾移植的存活率,有利于移植肾早期功能的恢复。
[Objective] To evaluate the different immunosuppression regimes on early graft functions after renal transplantation. [Methods] There are three immunosuppression regimes on graft survival after renal transplantation. Group A： Csa＋Aza＋Pred, Group B： Csa＋MMF＋ Pred, Group C： FK506＋ MMF＋ Pred. According to the early renal function after grafting, the survival rate in the first year, the incidences of side effect and related complication, acute rejection rate and revival rate were analyzed in each group. [Results] One-year graft survival in group B or group C was always higher than the group A. The incidence of acute rejection was the lowest in group C while the incidence of hepatic toxicities and renal toxicities was also lower than group A or group B. [ Conclusion] Through the comparison between the different clinical immunosuppression regimes, we believe that the application of the immunosuppression regimes composed by the MMF and FK506 has greater safety, which can decrease the acute rejection rate and incidence of drug side effect, and increase the grafted survival rate. It is advantageous to the revival of the early graft functions after renal transplantation.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2006年第21期3295-3297,共3页
China Journal of Modern Medicine
关键词
移植肾
免疫抑制剂
肾功能
kidney transplantation
immunosuppression
kidney function
